Login / Signup

Efficacy, safety, and tolerability of adjunctive brivaracetam in adult Asian patients with uncontrolled focal-onset seizures: A phase III randomized, double-blind, placebo-controlled trial.

Yushi InoueSomsak TiamkaoDong ZhouLeonor Cabral-LimKheng-Seang LimShih-Hui LimJing-Jane TsaiBrian MoseleyLin WangWeiwei SunYoshinobu HayakawaHiroshi SasamotoTomonobu SanoCarrie McClungAlmasa Bass
Published in: Epilepsia open (2024)
Brivaracetam is used to treat partial or focal seizures in people with epilepsy. Most studies with brivaracetam tablets have involved people from non-Asian racial backgrounds. In this study, 449 Asian adults with epilepsy took part. One third took 50 mg of brivaracetam, one third took 200 mg of brivaracetam, and one third took a placebo each day for 12 weeks. On average, those who took brivaracetam had fewer seizures than those given the placebo. Most of the side effects were mild and the number and type of side effects seen were as expected for this medication.
Keyphrases
  • double blind
  • phase iii
  • placebo controlled
  • clinical trial
  • open label
  • phase ii
  • study protocol
  • temporal lobe epilepsy
  • healthcare
  • randomized controlled trial
  • adverse drug
  • case control